SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Apr 29, 2016
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: April 29, 2016 · CIK: 0001385818 · Accession: 0001144204-16-097522
AI Filing Summary & Sentiment
File numbers found in text: 333-210144
Show Raw Text
CORRESP
1
filename1.htm
JOSEPH GUNNAR & CO., LLC
30 Broad Street, 11th Fl
New York, NY 10004
April 29, 2016
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
Aytu Bioscience, Inc. (the “Company”)
File No. 333-210144
Registration Statement on Form S-1
Ladies and Gentlemen:
Pursuant to Rule 461
of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended
(the “Securities Act”), we, the representative of the several underwriters (the “Representative”), hereby
join in the request of the Company that the effective time of the above-referenced Registration Statement be accelerated so that
it will be declared effective at 5:00 p.m. Eastern Time on Monday, May 2, 2016, or as soon thereafter as practicable.
Pursuant to Rule 460
under the Securities Act, please be advised that during the period from April 25, 2016 to the date of this letter, we, acting on
behalf of the several underwriters, distributed as many copies of the Preliminary Prospectuses, dated April 25, 2016 as appears
to be reasonable to secure adequate distribution of the Preliminary Prospectus.
Very truly yours,
JOSEPH GUNNAR & CO., LLC
By: /s/ Eric Lord
Name: Eric Lord
Title:
Head of Investment
Banking/Underwritings